EP1221868A1 - Supplement nutritionnel - Google Patents
Supplement nutritionnelInfo
- Publication number
- EP1221868A1 EP1221868A1 EP00969600A EP00969600A EP1221868A1 EP 1221868 A1 EP1221868 A1 EP 1221868A1 EP 00969600 A EP00969600 A EP 00969600A EP 00969600 A EP00969600 A EP 00969600A EP 1221868 A1 EP1221868 A1 EP 1221868A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- folate
- composition
- folic acid
- matter
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 85
- 235000019152 folic acid Nutrition 0.000 claims abstract description 60
- 239000011724 folic acid Substances 0.000 claims abstract description 60
- 229940014144 folate Drugs 0.000 claims abstract description 35
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960000304 folic acid Drugs 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 239000000047 product Substances 0.000 claims abstract description 11
- 235000018823 dietary intake Nutrition 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 239000013543 active substance Substances 0.000 claims abstract description 4
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000013589 supplement Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 claims description 2
- 238000005728 strengthening Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 19
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 18
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 15
- 108010010234 HDL Lipoproteins Proteins 0.000 description 8
- 102000015779 HDL Lipoproteins Human genes 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 208000029078 coronary artery disease Diseases 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- -1 folinic acid Chemical compound 0.000 description 3
- 235000008191 folinic acid Nutrition 0.000 description 3
- 239000011672 folinic acid Substances 0.000 description 3
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 3
- 229960001691 leucovorin Drugs 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- WYMSBXTXOHUIGT-UHFFFAOYSA-N paraoxon Chemical compound CCOP(=O)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 WYMSBXTXOHUIGT-UHFFFAOYSA-N 0.000 description 2
- 229960004623 paraoxon Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 108010009043 arylesterase Proteins 0.000 description 1
- 102000028848 arylesterase Human genes 0.000 description 1
- 230000000778 atheroprotective effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the object of the invention is the use of folic acid or folate or a functionally equivalent substance as a supplement or additive for the manufacture of a composition of matter for dietary intake with antioxidative defences enhancing effect.
- the term "effective amount” means an amount of the active agent which after administration is sufficient to enhance the serum paraoxonase activity and thus the antioxidative defences in the subject.
- folic acid and folate can be used interchangeably.
- the composition of matter can be any dietary, typically orally administered composition, preparation or product, such as a food or feed product, food supplement, a drug preparation, or a raw material for such a product.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
Abstract
La présente invention concerne un procédé destiné à la fabrication d'une composition de matière servant comme apport alimentaire, telle qu'un aliment ou un produit alimentaire ou un supplément nutritionnel, destinée à renforcer le système de défense à effet antioxydant d'un sujet, tel qu'un être humain. Ce procédé est caractérisé par le fait qu'un acide folique, un folate, ou une substance dont la fonction est équivalente, est ajouté à la composition comme agent actif.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI992239 | 1999-10-18 | ||
| FI992239A FI19992239A (fi) | 1999-10-18 | 1999-10-18 | Ravintotäydennys |
| PCT/FI2000/000899 WO2001028365A1 (fr) | 1999-10-18 | 2000-10-17 | Supplement nutritionnel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1221868A1 true EP1221868A1 (fr) | 2002-07-17 |
Family
ID=8555463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP00969600A Withdrawn EP1221868A1 (fr) | 1999-10-18 | 2000-10-17 | Supplement nutritionnel |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1221868A1 (fr) |
| JP (1) | JP2003511097A (fr) |
| AU (1) | AU7927200A (fr) |
| FI (1) | FI19992239A (fr) |
| WO (1) | WO2001028365A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420342B1 (en) * | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
| US6740746B2 (en) * | 2001-03-20 | 2004-05-25 | Oy Jurilab Ltd. | DNA molecule encoding a variant paraoxonase and uses thereof |
| DE10301354A1 (de) | 2003-01-16 | 2004-07-29 | Esa Patentverwertungsagentur Sachsen-Anhalt Gmbh | Verfahren zur Herstellung von Rohwurst mit beschleunigtem Reifeprozess |
| ES2302571B2 (es) * | 2005-03-18 | 2009-03-16 | Universidad Complutense De Madrid | Procedimiento de obtencion de embutidos cocidos enriquecidos con acido folico. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2105177A1 (fr) * | 1992-09-14 | 1994-03-15 | Willem Jacob Serfontein | Preparations pharmaceutiques pour la reduction des taux d'homocysteine |
| US5932624A (en) * | 1995-10-17 | 1999-08-03 | Herbert; Victor D. | Vitamin supplement composition |
| DE29808384U1 (de) * | 1998-05-08 | 1998-08-06 | Eckes Granini Gmbh Co Kg | Getränk |
| US6121249A (en) * | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
-
1999
- 1999-10-18 FI FI992239A patent/FI19992239A/fi unknown
-
2000
- 2000-10-17 EP EP00969600A patent/EP1221868A1/fr not_active Withdrawn
- 2000-10-17 JP JP2001530969A patent/JP2003511097A/ja not_active Withdrawn
- 2000-10-17 WO PCT/FI2000/000899 patent/WO2001028365A1/fr not_active Application Discontinuation
- 2000-10-17 AU AU79272/00A patent/AU7927200A/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0128365A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001028365A1 (fr) | 2001-04-26 |
| AU7927200A (en) | 2001-04-30 |
| FI19992239A (fi) | 2001-04-19 |
| JP2003511097A (ja) | 2003-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9872844B2 (en) | Compositions and methods for the reduction or prevention of hepatic steatosis | |
| US11547736B2 (en) | Sauvignon blanc grape seed products for nonalcoholic fatty liver disease | |
| US7968529B2 (en) | Use of sphingolipids for reducing high plasma cholesterol and high triacylglycerol levels | |
| JP2009525990A (ja) | 医薬組成物 | |
| WO2012097061A1 (fr) | Compositions nutritionnelles et procédés pour améliorer le métabolisme protéique des muscles squelettiques | |
| EA025256B1 (ru) | Композиция, подходящая для лечения нарушений липидного обмена | |
| US20170239253A1 (en) | Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash) | |
| KR20210135551A (ko) | 개선된 생체이용률을 갖는 중쇄 트리글리세라이드 제제 및 이와 관련된 방법 | |
| US20220387464A1 (en) | Inositol phosphate-containing composition | |
| US6265391B1 (en) | Method for preventing peripheral nerve damage | |
| EP2030629A1 (fr) | Agent d'amélioration du métabolisme des lipides | |
| EP1221868A1 (fr) | Supplement nutritionnel | |
| US20230040395A1 (en) | Composition for suppressing obesity | |
| JP5584411B2 (ja) | ホモシステイン低下用組成物 | |
| JP2008156264A (ja) | ルイボスティーの食後高血糖および血中尿酸低下作用 | |
| EP3991728A1 (fr) | Agent inhibiteur de fibrose hépatique et agent activateur de cellules adipeuses brunes contenant de la taxifoline | |
| US20100028457A1 (en) | Agent for prevention or treatment of blood glucose level elevation | |
| EP0595006A1 (fr) | Compositions pharmaceutiques et diététiques contenant de la vitamin B6, de l'acide folique et de la vitamine B12 pour le traitement des maladies métaboliques des enfants | |
| JPWO2008136173A1 (ja) | スチルベン誘導体を有効成分とする脂肪細胞分化抑制剤 | |
| KR101699123B1 (ko) | 코르티코스테론 저하용 조성물 | |
| JP2022169385A (ja) | タモギタケ又はその処理物を有効成分として含む、脂質代謝改善剤 | |
| Ashfield-Watt et al. | Folate, homocysteine, and heart disease. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20020404 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| 17Q | First examination report despatched |
Effective date: 20040720 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20041201 |